Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2025.1595028 Oncology Correction Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study Nyen Johanne Elise 1 * Booth Anja Ødegård 2 † Husby Øyvind 2 Bugge Christoffer 1 Engebretsen Ingrid 1 Oteiza Francisco 1 Helland Åslaug 3 4 Fjellbirkeland Lars 3 5 Brustugun Odd Terje 3 6 Grønberg Bjørn Henning 7 8 1 Oslo Economics, Oslo, Norway 2 Pfizer AS, Oslo, Norway 3 Institute of Clinical Medicine, University of Oslo, Oslo, Norway 4 Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway 5 Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway 6 Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway 7 Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway 8 Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Johanne Elise Nyen, jen@osloeconomics.no

†Present address: Anja Ødegård Booth, AstraZeneca AS, Oslo, Norway

 26 03 2025 2025 15 1595028 17 03 2025 18 03 2025 Copyright © 2025 Nyen, Booth, Husby, Bugge, Engebretsen, Oteiza, Helland, Fjellbirkeland, Brustugun and Grønberg 2025 Nyen, Booth, Husby, Bugge, Engebretsen, Oteiza, Helland, Fjellbirkeland, Brustugun and Grønberg

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study by Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT and Grønberg BH (2025). Front. Oncol. 15:1506041. doi: 10.3389/fonc.2025.1506041 ROS ALK EGFR real world data lung cancer time on treatment section-in-acceptance Thoracic Oncology

In the published article, there was an error. The ClinicalTrials.gov-identifier of our study was not included in the publication.

A correction has been made to Materials and methods, Reporting guidelines and ethics, Paragraph 1. This sentence previously stated:

“The study was approved by the Regional Ethics Committee of Norway South-East D (Reference number 485084)”.

The corrected sentence appears below:

“The study was approved by the Regional Ethics Committee of Norway South-East D (Reference number 485084) and registered at http://ClinicalTrials.gov (Reference number NCT05834348)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.